Patent Theme
Cellular Immunotherapy
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
9,720 US filings from 3,218 companies since 2023 · 2023: 2,337 · 2024: 3,198 · 2025: 2,936 · 2026 YTD: 1,249
Therapeutic Activity (Pharma)
Top companies
Ranked by filings in this theme since 2023. 2026 is partial.
| # | Company | Since 2023 | 2023 | 2024 | 2025 | 2026 YTD | YoY |
|---|
| 1 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 211 | 46 | 82 | 58 | 25 | -29.3% |
| 2 | The Regents of the University of California | 189 | 41 | 56 | 67 | 25 | +19.6% |
| 3 | Memorial Sloan Kettering Cancer Center | 124 | 25 | 45 | 38 | 16 | -15.6% |
| 4 | Iovance Biotherapeutics, Inc. | 114 | 27 | 40 | 27 | 20 | -32.5% |
| 5 | Board of Regents, The University of Texas System | 110 | 28 | 35 | 35 | 12 | 0.0% |
| 6 | The Board of Trustees of the Leland Stanford Junior University | 108 | 28 | 36 | 29 | 15 | -19.4% |
| 7 | Novartis AG | 99 | 25 | 34 | 26 | 14 | -23.5% |
| 8 | Bristol-Myers Squibb Company | 90 | 15 | 35 | 26 | 14 | -25.7% |
| 9 | Regeneron Pharmaceuticals, Inc. | 90 | 13 | 28 | 33 | 16 | +17.9% |
| 10 | City of Hope | 88 | 21 | 22 | 33 | 12 | +50.0% |
| 11 | The General Hospital Corporation | 79 | 16 | 25 | 28 | 10 | +12.0% |
| 12 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 79 | 15 | 37 | 20 | 7 | -45.9% |
| 13 | Hoffmann-La Roche Inc. | 76 | 17 | 27 | 21 | 11 | -22.2% |
| 14 | Immatics Biotechnologies GmbH | 76 | 21 | 43 | 12 | · | -72.1% |
| 15 | The United States of America, as represented by the Secretary, Department of Health and Human Services | 74 | 15 | 24 | 23 | 12 | -4.2% |
| 16 | AUTOLUS LIMITED | 70 | 21 | 19 | 22 | 8 | +15.8% |
| 17 | Cue Biopharma, Inc. | 70 | 16 | 31 | 19 | 4 | -38.7% |
| 18 | ImmunityBio, Inc. | 69 | 5 | 21 | 30 | 13 | +42.9% |
| 19 | Dana-Farber Cancer Institute, Inc. | 68 | 14 | 19 | 22 | 13 | +15.8% |
| 20 | Kite Pharma, Inc. | 68 | 13 | 23 | 22 | 10 | -4.3% |
| 21 | Juno Therapeutics, Inc. | 63 | 16 | 17 | 21 | 9 | +23.5% |
| 22 | Genentech, Inc. | 61 | 13 | 22 | 18 | 8 | -18.2% |
| 23 | Cellectis | 52 | 14 | 20 | 12 | 6 | -40.0% |
| 24 | BAYLOR COLLEGE OF MEDICINE | 51 | 14 | 16 | 14 | 7 | -12.5% |
| 25 | Regents of the University of Minnesota | 51 | 10 | 17 | 20 | 4 | +17.6% |